Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1002)	6/9/1999 9:14:00 PM
From: P.M.Freedman	Read Replies (1) \| Respond to of 1686

A company who treasures its own stock for company's stock option plan can be accounted as asset. The conclusion for the nearly saturated Avonex markets is based on the following facts: 1. Relative small patient population of MS. Let's say 300,000 in the US (in the world?) as the article said. 2. Low percentage efficiency. Only 1/3 of MS patients will be benefited from Avonex. 3. High price. Monthly over $1000 is minimum expense. Only those who is using government's or our tax $$$ will like to take. Good luck!